Search

Your search keyword '"Cao, Weiwei"' showing total 26 results
Start Over Author "Cao, Weiwei" Publisher wiley
26 results on '"Cao, Weiwei"'

9. Highly Nonstoichiometric YAG Ceramics with Modified Luminescence Properties

Author

Cao, Weiwei, primary, Becerro, Ana Isabel, additional, Castaing, Victor, additional, Fang, Xue, additional, Florian, Pierre, additional, Fayon, Franck, additional, Zanghi, Didier, additional, Veron, Emmanuel, additional, Zandonà, Alessio, additional, Genevois, Cécile, additional, Pitcher, Michael J., additional, and Allix, Mathieu, additional

Published
2023
Full Text
View/download PDF

12. FMRNet: A fused network of multiple tumoral regions for breast tumor classification with ultrasound images

Author

Gang Yuan, Wenju Cui, Zhuangzhi Yan, Cao Yuzhu, Cao Weiwei, Jian Zheng, Zhengda Lu, Xinye Ni, and Yunsong Peng

Subjects
Channel (digital image), Computer science, business.industry, Ultrasound, Breast Neoplasms, Pattern recognition, General Medicine, Convolutional neural network, Breast tumor, Set (abstract data type), Image Processing, Computer-Assisted, Fuse (electrical), Humans, Female, Segmentation, Breast, Neural Networks, Computer, Ultrasonography, Mammary, Artificial intelligence, Focus (optics), business, Ultrasonography
Abstract

Purpose Recent studies have illustrated that the peritumoral regions of medical images have value for clinical diagnosis. However, the existing approaches using peritumoral regions mainly focus on the diagnostic capability of the single region and ignore the advantages of effectively fusing the intratumoral and peritumoral regions. In addition, these methods need accurate segmentation masks in the testing stage, which are tedious and inconvenient in clinical applications. To address these issues, we construct a deep convolutional neural network that can adaptively fuse the information of multiple tumoral-regions (FMRNet) for breast tumor classification using ultrasound (US) images without segmentation masks in the testing stage. Methods To sufficiently excavate the potential relationship, we design a fused network and two independent modules to extract and fuse features of multiple regions simultaneously. First, we introduce two enhanced combined-tumoral (EC) region modules, aiming to enhance the combined-tumoral features gradually. Then we further design a three-branch module for extracting and fusing the features of intratumoral, peritumoral, and combined-tumoral regions, denoted as the IPC module. Especially, we design a novel fusion module by introducing a channel attention module to adaptively fuse the features of three regions. The model is evaluated on two public datasets including UDIAT and BUSI with breast tumor ultrasound images. Two independent groups of experiments are performed on two respective datasets using the five-fold stratified cross-validation strategy. Finally, we conduct ablation experiments on two datasets, in which BUSI is used as the training set and UDIAT is used as the testing set. Results We conduct detailed ablation experiments about the proposed two modules and comparative experiments with other existing representative methods. The experimental results show that the proposed method yields state-of-the-art performance on both two datasets. Especially, in the UDIAT dataset, the proposed FMRNet achieves a high accuracy of 0.945 and a specificity of 0.945 respectively. Moreover, the precision (PRE = 0.909) even dramatically improves by 21.6% on the BUSI dataset compared with the existing method of the best result. Conclusion The proposed FMRNet shows good performance in breast tumor classification with US images, and proves its capability of exploiting and fusing the information of multiple tumoral-regions. Furthermore, the FMRNet has potential value in classifying other types of cancers using multiple tumoral-regions of other kinds of medical images. This article is protected by copyright. All rights reserved.

Published
2021

15. A novel natural PPARγ agonist, Gypenoside LXXV, ameliorates cognitive deficits by enhancing brain glucose uptake via the activation of Akt/GLUT4 signaling in db/db mice

Author

Meng, Xiangbao, primary, Zhang, Yuan, additional, Li, Zongyang, additional, Hu, Jinxian, additional, Zhang, Di, additional, Cao, Weiwei, additional, Li, Min, additional, Ma, Guoxu, additional, Wang, Sicen, additional, Cui, Ping, additional, Cai, Qian, additional, and Huang, Guodong, additional

Published
2022
Full Text
View/download PDF

16. A novel DPP ‐4 inhibitor Gramcyclin A attenuates cognitive deficits in APP / PS1 /tau triple transgenic mice via enhancing brain GLP ‐1‐dependent glucose uptake

Author

Li, Zongyang, primary, Zhang, Yuan, additional, Meng, Xiangbao, additional, Li, Min, additional, Cao, Weiwei, additional, Yang, Junshan, additional, Xu, Xudong, additional, Liu, Wenlan, additional, Li, Weiping, additional, Cai, Qian, additional, Wang, Sicen, additional, Ma, Guoxu, additional, Liu, Zhiheng, additional, and Huang, Guodong, additional

Published
2022
Full Text
View/download PDF

24. Increasing brain glucose uptake by Gypenoside LXXV ameliorates cognitive deficits in a mouse model of diabetic Alzheimer's disease.

Author

Meng X, Zhang Y, Li Z, Ma G, Zhang X, Zhang D, Cao W, Wang S, Cai Q, Cui P, and Huang G

Subjects
Mice, Animals, PPAR gamma metabolism, Phosphatidylinositol 3-Kinases metabolism, Proto-Oncogene Proteins c-akt metabolism, Mice, Transgenic, Amyloid beta-Peptides metabolism, Disease Models, Animal, Brain, Glucose metabolism, Cognition, Amyloid beta-Protein Precursor metabolism, Alzheimer Disease metabolism, Cognitive Dysfunction drug therapy, Diabetes Mellitus
Abstract

We have previously reported that Gypenoside LXXV (GP-75), a novel natural PPARγ agonist isolated from Gynostemma pentaphyllum, ameliorated cognitive deficits in db/db mice. In this study, we further investigated the beneficial effects on cognitive impairment in APP/PS1 mice and a mouse model of diabetic AD (APP/PS1xdb/db mice). Interestingly, intragastric administration of GP-75 (40 mg/kg/day) for 3 months significantly attenuated cognitive deficits in APP/PS1 and APP/PS1xdb/db mice. GP-75 treatment markedly reduced the levels of glucose, HbA1c and insulin in serum and improved glucose tolerance and insulin sensitivity in APP/PS1xdb/db mice. Notably, GP-75 treatment decreased the β-amyloid (Aβ) burden, as measured by 11 C-PIB PET imaging. Importantly, GP-75 treatment increased brain glucose uptake as measured by 18 F-FDG PET imaging. Moreover, GP-75 treatment upregulated PPARγ and increased phosphorylation of Akt (Ser473) and GLUT4 expression levels but decreased phosphorylation of IRS-1 (Ser616) in the hippocampi of both APP/PS1 and APP/PS1xdb/db mice. Furthermore, GP-75-induced increases in GLUT4 membrane translocation in primary hippocampal neurons from APP/PS1xdb/db mice was abolished by cotreatment with the selective PPARγ antagonist GW9662 or the PI3K inhibitor LY294002. In summary, GP-75 ameliorated cognitive deficits in APP/PS1 and APP/PS1xdb/db mice by enhancing glucose uptake via activation of the PPARγ/Akt/GLUT4 signaling pathways., (© 2022 John Wiley & Sons Ltd.)

Published
2023
Full Text
View/download PDF

25. Protective effects of di-caffeoylquinic acids from Artemisia selengensis Turcz leaves against monosodium urate-induced inflammation via the modulation of NLRP3 inflammasome and Nrf2 signaling pathway in THP-1 macrophages.

Author

Cao W, Wu T, Liang F, Fang Y, Cheng Y, Pan S, and Xu X

Subjects
Inflammasomes, Inflammation chemically induced, Inflammation drug therapy, Inflammation metabolism, Interleukin-1beta genetics, Interleukin-1beta metabolism, Macrophages, NF-E2-Related Factor 2 genetics, NF-E2-Related Factor 2 metabolism, NLR Family, Pyrin Domain-Containing 3 Protein genetics, Signal Transduction, Uric Acid, Artemisia metabolism, Gout chemically induced, Gout drug therapy, Gout metabolism
Abstract

Artemisia selengensis Turcz (AST) as a common vegetable is rich in di-caffeoylquinic acids (di-CQAs) and has been reported to possess multiple health benefits. However, whether di-CQAs from AST leaf extracts (ASTE) could alleviate gout inflammation is still unknown. Herein, this study explored the inhibitory mechanism of ASTE on gout inflammation in THP-1 macrophages. Results suggested that ASTE suppressed the secretion and mRNA levels of inflammatory cytokines including interleukin-18, interleukin-1β, interleukin-6, and tumor necrosis factor-α. Pretreatment with ASTE inhibited lipopolysaccharide-induced of IκBα degradation, p65 phosphorylation and up-regulation of Nucleotide-binding oligomerization domain-like receptor containing pyrin domain 3 (NLRP3) inflammasome proteins. Moreover, ASTE inhibited monosodium urate-induced the up-regulation of active caspase-1 and interleukin-1β, promoted nuclear factor E2-related factor2 (Nrf2) to translocate into the nucleus, reducing the generation of MSU-induced reactive oxygen species. These results suggested that ASTE alleviated gout inflammation via inhibiting NLRP3 inflammasome activation and activating Nrf2 signaling pathway. PRACTICAL APPLICATIONS: Artemisia selengensis Turcz (AST) as a common vegetable in China belongs to genus Artemisia, which are rich in di-caffeoylquinic acids. This study aimed to investigate the effect of ASTE on alleviating gout inflammation and whether NLRP3 inflammasome and Nrf2 signaling pathways are involved in the protection of ASTE against gout inflammation. Our findings are significant for developing di-CQAs from AST by-products as an effective functional food for preventing gout., (© 2022 Wiley Periodicals LLC.)

Published
2022
Full Text
View/download PDF

26. A novel DPP-4 inhibitor Gramcyclin A attenuates cognitive deficits in APP/PS1/tau triple transgenic mice via enhancing brain GLP-1-dependent glucose uptake.

Author

Li Z, Zhang Y, Meng X, Li M, Cao W, Yang J, Xu X, Liu W, Li W, Cai Q, Wang S, Ma G, Liu Z, and Huang G

Subjects
Amyloid beta-Peptides metabolism, Amyloid beta-Protein Precursor genetics, Amyloid beta-Protein Precursor metabolism, Amyloid beta-Protein Precursor pharmacology, Animals, Brain, Cognition, Disease Models, Animal, Glucagon-Like Peptide 1 metabolism, Glucagon-Like Peptide 1 pharmacology, Glucagon-Like Peptide 1 therapeutic use, Glucose metabolism, Hippocampus, Mice, Mice, Transgenic, Alzheimer Disease drug therapy, Alzheimer Disease metabolism, Cognitive Dysfunction drug therapy, Dipeptidyl-Peptidase IV Inhibitors pharmacology
Abstract

Enhancing glucagon-like peptide 1 (GLP-1) signaling with a dipeptidyl peptidase IV (DPP-4) inhibitor might exert protective effects on Alzheimer's disease (AD). We found that intragastric administration of Gramcyclin A (10, 20 and 40 mg/kg), a novel DPP-4 inhibitor, for 3 months significantly reversed cognitive decline in APP/PS1/tau triple transgenic mice in a dose-dependent manner. Gramcyclin A treatment markedly reduced Aβ plaques as well as the insoluble and soluble forms of Aβ40 and Aβ42 in the hippocampus of APP/PS1/tau mice. Treatment with Gramcyclin A remarkedly decreased the level of microglia and suppressed neuroinflammation in the hippocampus of APP/PS1/tau mice. Moreover, Gramcyclin A treatment could increase brain glucose uptake in APP/PS1/tau mice, as detected by 18-fluoro-2-deoxyglucose ( 18 F-FDG) micro-positron emission tomography (micro-PET) imaging. Furthermore, Gramcyclin A significantly increased expression of glucagon-like peptide-1 (GLP-1), GLP-1R, proliferator-activated receptor gamma coactivator (PGC)-1α and glucose transporter 4 (GLUT4), and inhibited insulin receptor (IRS)-1 phosphorylation and tau hyperphosphorylation in the hippocampus of APP/PS1/tau mice. Collectively, Gramcyclin A conferred protective effects against AD via enhancing brain GLP-1-dependent glucose uptake. The DPP-4 inhibitor Gramcyclin A might be a potential therapeutic drug for AD., (© 2022 John Wiley & Sons Ltd.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results